The drug landscape in India is increasingly characterized by a pattern toward market concentration, with a handful of major companies wielding significant power. These industry giants, often bolstered by long-standing distribution networks and robust brand recognition, present a challenging picture for competition and affordable healthcare. While s

The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces increasing concerns about monopolies. A few dominant companies control a significant share of the market, potentially restricting competition and driving up prices for consumers. This concern raises questions about the long-term impact on patient access to